Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
Spyros ChalkiasNichole McGheeJordan L WhatleyBrandon EssinkAdam BroszJoanne E TomassiniBethany GirardDarin K EdwardsKai WuArshan NasirDiana LeeLaura E AvenaJing FengWeiping DengDavid C MontefioriLindsey R BadenJacqueline M MillerRituparna DasPublished in: The Journal of infectious diseases (2024)
XBB.1.5-containing mRNA-1273 vaccines elicit robust, diverse nAb responses against more recent SARS-CoV-2 variants, including JN.1, supporting the XBB.1.5-spike update for COVID-19 vaccines.